Abstract： Ovarian cancer is a common gynecological malignant tumor with high recurrence rate and poor prognosis.Poly ADP ribose polymerase inhibitors(PARPi)as a novel type of small molecule targeted drugs have achieved good effect in the treatment of ovarian cancer,however,resistance to PARPi has become a great challenge clinically.With the increasing application of PARPi,overcoming drug resistance has be-come the focus of clinical studies.Clinical trials have confirmed the feasibility of re-treatment with PARPi in ovarian cancer patients after drug resistance.The combined application of PARPi with anti-angiogenic agents,immune checkpoint inhibitors and other drugs has been explored to restore PARPi sensitivity after resistance.In this paper,we review the mechanisms of PARPi resistance and new strategies of re-treatment with PARPi in ovarian cancer patients after resistance occurred.